Privi Speciality Chemicals Limited has informed the Exchange about General Updates - Not to proceed with capital raising by way of QIP
PRIVISCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Privi Speciality Chemicals has decided not to go ahead with its earlier plan to raise up to ₹1,000 crore through a Qualified Institutions Placement (QIP) of equity shares, which was approved in May and August 2024. The Board cited the company's improved performance and sufficient cash accruals to meet capital expenditure needs as the reason for dropping the fundraising. Separately, the Board approved a scheme of amalgamation to merge two related entities — Privi Fine Sciences Private Limited (a related party) and Privi Biotechnologies Private Limited (a wholly-owned subsidiary) — into Privi Speciality Chemicals. The merger involves no cash payout and will be executed through a share exchange, with promoter group holding expected to rise from 74.05% to 74.67% post-merger. The scheme still requires approvals from NCLT, SEBI, stock exchanges, shareholders, and creditors.
Positive for shareholders as the ₹1,000 crore QIP dilution is off the table, signalling financial strength and adequate internal cashflows. The merger will cause a marginal increase in promoter shareholding (from 74.05% to 74.67%) and a slight dilution for public shareholders, though the company states it will be value-accretive and conserve cash compared to the earlier proposed cash acquisition.